CYC065 Inhibitor

Solid. Powder

98.00%

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

397.52

DMSO: 100mg/mL (251.56mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

C21H31N7O

CC[C@@H]([C@@H](C)O)Nc1nc(NCc2c(C)cc(C)nc2)c2ncn(C(C)C)c2n1

1070790-89-4

Briefly, tumour cells are plated in six-well plates and treated with a titration of CYC065 concentrations (i.e., ranging from 100 to 500nM). After 72h, cells are harvested, washed and stained with propidium iodide (PI; 5ug/mL) for flow cytometric counts. The percentage of viable cells is then normalized considering the vehicle-treated cells as 100% viable. Half-maximal inhibitory concentration values are determined using GraphPad Prism5 version 6. For drug combination studies, USC-ARK-1 and USC-ARK-2 cell lines are incubated with the combination of Taselisib and CYC065 at multiple paired concentrations including the IC50, the IC50/2 and the IC50*2 of each cell line to the corresponding drug (i.e., 10nM of Taselisib and 198nM of CYC065 for USC-ARK-1 and 50nM of Taselisib and 62.5nM of CYC065 for USC-ARK-2). Synergism is assessed by the combination index (CI). CI values <1 define a synergistic activity of the combination treatment, The CI values are calculated using the CompuSyn software [1].

Cell Cycle/Checkpoint; CDK